Successfull use of propranolol in segmental hemangioma: A case report

Abstract

The treatment of hemangiomas in infancy may be associated with significant morbidity. In addition to morbidity, an objective response cannot be obtained because of the absence of targeted therapeutic options. Herein, we present an infant with a segmental hemangioma and marked glucocorticoid toxicity due to prior steroid therapy that was successfully treated with propranolol. Propranolol was tolerated well and no side effects were observed during the treatment. The only problem to occur was disease recurrence following the withdrawal of propranolol at age 13 months, which was not within the age of spontaneous regression (generally considered as >18 months).

In response to “Megadose Methylprednisolone (MDMP) for Hemangiomatosis”

“…We are grateful to Dr. Özsoylu for his valuable comments on our case report concerning the treatment of hemangiomatosis with propranolol [1]. One of the issues raised by Dr. Özsoylu is regarding with the terminology used to describe hemangiomatous lesions.…”

İnfantil hemanjiyomlarda steroidlerden propranolole gelişen tedavi stratejisi

“…The impressive discovery of efficacy of propranolol in treatment of infantile hemangiomas (IH) represent an effective, inexpensive, readily available and safe therapeutic innovation for most of the cases with IH. In many centers propranolol has become the first line treatment option in treatment of IH [1][2][3][4][5] . Large-scale phase III clinical trials are needed to determine optimal dosing for propranolol and long-term safety profiles.…”

Megadose Methylprednisolone (MDMP) for Hemangiomatosis

“…Küpeli and his colleagues[1] should be congratulated for their success in treating hemangiomatosis, which could be life threatining depending on the localization of hemangiomas, with propranolol. I prefer the term infantile hemangiomatosis instead of segmental hemangiomatosis[2] for the authors’ patient.…”